2
项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的临床试验The Safety and Clinical Efficacy of Dasatinib Plus Human CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Subjects With Ph-positive Acute Lymphoblastic Leukemia
To evaluate the safety and efficacy of Dasatinib plus CD19/CD22 Bispecific CAR-T for the treatment of elderly Ph-positive lymphoblastic leukemia. Newly diagnosed Ph-positive patients will be given Dasatinib plus VP chemotherapy for induction treatment,if a hematologic complete remission was observed then a lymphocyte collection will be administrated to patients. Then chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells
The Safety and Clinical Efficacy of Human CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR)-T Cell Therapy for Subjects With Measurable Residual Disease(MRD)-Positive B Cell Acute Lymphoblastic Leukemia
To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells.
100 项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的临床结果
100 项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的转化医学
100 项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的专利（医药）
1
项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的文献（医药）2020-04-01·Leukemia research
Daratumumab for quick and sustained remission in post-transplant relapsed/refractory acute lymphoblastic leukemia
Letter
作者: Wang, Jingbo ; Zhang, Yongping ; Liu, Fuhong ; Xue, Song
A case of 31-yr-old adult patient with acute lymphoblastic leukemia (ALL) who relapsed post allogenic hematopoietic stem cell transplantation (HSCT) and was resistant to treatment with donor lymphocyte infusion (DLI) and anti-CD19/CD22 CAR-T cells is reported.He was salvaged with a single dose treatment of daratumumab and achieved flow-based measurable residual disease (MRD) negativity (< 0.01%) quickly.MRD is an important predictor of outcome in ALL measured using multi-parametric flow cytometry and the analytic sensitivity is conventionally 0.01%, i.e., detection of one leukemic cell in up to 10,000 normal nucleated cells.The patient is currently 16 wk post daratumumab initiation with deep complete remission and good performance status.
100 项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的药物交易
